NEWSROOM

Medtronic Expands Diabetes Support Programs to Help Customers Losing Insurance Coverage Due to Job Loss as a Result of COVID-19

May 06, 2020

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an expansion of the Medtronic Assurance program with a new option to support diabetes customers who have lost their health insurance due to COVID-19-related job loss. Current eligible U.S. customers can now receive a 3-month supply of glucose sensors, infusion sets and reservoirs at no cost.

Read more >

Medtronic Gives $1 Million in Product Donations to Insulin for Life to Support COVID-19 Relief Efforts

April 30, 2020

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a $1 million product donation to Insulin for Life USA to support COVID-19 relief efforts. Medtronic will donate sensors, infusion sets and reservoirs, which will be distributed by Insulin for Life USA to patients on insulin pump therapy experiencing financial hardships as a result of COVID-19. Insulin for Life USA, with support from the Leona M. and Harry B. Helmsley Charitable Trust, will provide these supplies to approximately 15 diabetes clinics across the U.S. that serve people in need living with type 1 diabetes. Insulin for Life USA is a non-profit that supports continuity of therapy for people living with diabetes who otherwise would go without these critical and often life-saving supplies.

Read more >

Medtronic Acquires Klue

December 17,2019

DUBLIN - Dec. 17, 2019 (GLOBE NEWSWIRE) – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has completed the acquisition of Klue, a software company focused on behavior tracking that can provide real-time insights into when a person is consuming food. Klue’s technology is expected to be incorporated into the Medtronic Personalized Closed Loop (PCL) insulin pump system, currently in development.

Read more >

Medtronic Partners with Capital District Physicians’ Health Plan, Inc. (CDPHP) on Outcomes-Based Agreement to Increase Quality and Improve Access to Critical Diabetes Care

August 14, 2019

DUBLIN - August 14, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Capital District Physicians' Health Plan, Inc. (CDPHP) today announced an innovative outcomes-based agreement for individuals with type 1 and type 2 diabetes that utilize a Medtronic insulin pump. Under the strategic partnership, Medtronic will provide eligible CDPHP members access to state-of-the-art technologies, supplies, and education and training support services to manage their diabetes. Additionally, a component of Medtronic's reimbursement will be tied to successfully meeting agreed upon clinical improvement thresholds for enrolled members – such as A1C reduction, increased Time in Range, and reduced hypoglycemic events.

Read more >

Real-World Data from Guardian™ Connect and Sugar.IQ™ Reveal Improved Diabetes Outcomes

June 10, 2019

DUBLIN and SAN FRANCISCO - June 10, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world data on its Guardian™ Connect continuous glucose monitoring (CGM) system and Sugar.IQ™ diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco.

Read more >

View all Announcements >





Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Cho
Sr Director, Global Communications
818-576-5014
janet.cho@medtronic.com

Pamela Reese
Director, Communications
818-576-3398
pamela.s.reese@medtronic.com

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits